Enalaprilum [Inn-Latin] en es it fr


Enalaprilum [Inn-Latin] Marchi, Enalaprilum [Inn-Latin] Analoghi

Enalaprilum [Inn-Latin] Marchi miscela

  • Vaseretic (Enalapril Maleate + Hydrochlorothiazide)
  • Enalaprilum [Inn-Latin] Formula chimica


    Enalaprilum [Inn-Latin] RX link


    Enalaprilum [Inn-Latin] FDA foglio

    Enalaprilum_[Inn-Latin] FDA

    Enalaprilum [Inn-Latin] DMS (foglio di materiale di sicurezza)

    Enalaprilum [Inn-Latin] Sintesi di riferimento

    Patchett A. et al. Nature 288, 280 (1980)

    Enalaprilum [Inn-Latin] Peso molecolare

    376.447 g/mol

    Enalaprilum [Inn-Latin] Temperatura di fusione


    Enalaprilum [Inn-Latin] H2O Solubilita


    Enalaprilum [Inn-Latin] Stato


    Enalaprilum [Inn-Latin] LogP


    Enalaprilum [Inn-Latin] Forme di dosaggio

    Tablet; IV iniezione

    Enalaprilum [Inn-Latin] Indicazione

    Per il trattamento dell'ipertensione e dell'insufficienza cardiaca. Può essere usato da solo o in combinazione con diuretici tiazidici.

    Enalaprilum [Inn-Latin] Farmacologia

    Enalapril, un inibitore dell'enzima di conversione dell'angiotensina (ACE), è un profarmaco che viene utilizzato quando idrolizzato dalla estarases enalaprilato al suo attivo, per trattare l'ipertensione e lo scompenso cardiaco, per ridurre la proteinuria e la malattia renale in pazienti affetti da nefropatie, e per prevenire l'ictus, infarto miocardico e morte cardiaca in pazienti ad alto rischio. Enalapril e enalaprilato inibire enzima di conversione dell'angiotensina (ACE) in soggetti umani e animali. ACE è una peptidildipeptidasi che catalizza la conversione dell'angiotensina I alla sostanza vasocostrittore, l'angiotensina II. L'angiotensina II stimola anche l'aldosterone secrezione dalla corteccia surrenale.

    Enalaprilum [Inn-Latin] Assorbimento


    Enalaprilum [Inn-Latin] Tossicita


    Enalaprilum [Inn-Latin] Informazioni paziente

    Angioedema: Angioedema, including laryngeal edema, may occur at any time during treatment with angiotensin converting enzyme inhibitors, including enalapril. Patients should be so advised and told to report immediately any signs or symptoms suggesting angioedema (swelling of face, extremities, eyes, lips, tongue, difficulty in swallowing or breathing) and to take no more drug until they have consulted with the prescribing physician.

    Hypotension: Patients should be cautioned to report lightheadedness, especially during the first few days of therapy. If actual syncope occurs, the patients should be told to discontinue the drug until they have consulted with the prescribing physician.

    All patients should be cautioned that excessive perspiration and dehydration may lead to an excessive fall in blood pressure because of reduction in fluid volume. Other causes of volume depletion such as vomiting or diarrhea may also lead to a fall in blood pressure; patients should be advised to consult with the physician.

    Hyperkalemia: Patients should be told not to use salt substitutes containing potassium without consulting their physician. Neutropenia: Patients should be told to report promptly any indication of infection (e.g., sore throat, fever) which may be a sign of neutropenia.

    Pregnancy: Female patients of childbearing age should be told about the consequences of second- and third-trimester exposure to ACE inhibitors, and they should also be told that these consequences do not appear to have resulted from intrauterine ACEinhibitor exposure that has been limited to the first trimester. These patients should be asked to report pregnancies to their physicians as soon as possible.

    NOTE: As with many other drugs, certain advice to patients being treated with enalapril is warranted. This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.

    Enalaprilum [Inn-Latin] Atto interessato organismi

    Gli esseri umani e altri mammiferi